Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
about
A sequential approach with imatinib, chemotherapy and transplant for adult Ph+ acute lymphoblastic leukemia: final results of the GIMEMA LAL 0904 study.First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testingSusceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia.Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 studyNew approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.Philadelphia chromosome-positive acute lymphoblastic leukemia.Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemia.Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.Philadelphia chromosome-positive acute lymphoblastic leukemia in childhood.Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study
P2860
Q33822032-88C128CA-9781-4B0B-AF0C-23E070D139A3Q33843477-4839DDEE-42E3-4704-A21A-59004987AF89Q33915980-22ACB1DB-8AFB-4F93-88E8-4C1B4A2EB48AQ34425875-6C628346-F90E-41B9-90C4-0B93AC9943AFQ34557165-F075F41D-FA4A-4412-BE92-CDD1D57BE58EQ35146312-DB626DE9-3F03-40AD-9BEC-E231224941AEQ35571035-7DA900AB-157A-497E-84ED-F1E971D143CAQ36123315-AA197B5A-7A63-4E65-8C5D-8743092F40B8Q37069791-3CB8DF46-CD02-47C8-9F87-53E72EE0598BQ37344050-6066008F-E5C1-4CB4-9C64-75C1EFA784A6Q37389544-3BD1107A-B06E-4D38-8AE6-1320348AA631Q37545067-6AC58A6A-80AD-4564-80BF-0C1179FA8BCAQ37613888-9637A721-D580-410C-96DA-B03F5F7B670CQ37632798-BC440EDE-9355-4B49-B502-5E75FA164D98Q37887580-7C4B5286-27E9-4F97-9943-3B942299A3D9Q38792016-5030ED88-9EE6-452B-B1F3-E99E1F17E438Q39112294-22CC28FE-0A89-4646-91C0-E44CD9C1A9B3Q40817830-96CCCD76-3BB9-4F08-B056-FCB474C64F61Q42769654-A78964A7-E12A-45A9-937F-CF94932E2C14Q56997440-8748E675-003B-4824-B790-62AEFF59A0F6
P2860
Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Significant reduction of the h ...... acute lymphoblastic leukemia.
@en
Significant reduction of the h ...... acute lymphoblastic leukemia.
@nl
type
label
Significant reduction of the h ...... acute lymphoblastic leukemia.
@en
Significant reduction of the h ...... acute lymphoblastic leukemia.
@nl
prefLabel
Significant reduction of the h ...... acute lymphoblastic leukemia.
@en
Significant reduction of the h ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Significant reduction of the h ...... e acute lymphoblastic leukemia
@en
P2093
F Mandelli
G Martinelli
GIMEMA group
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403683
P50
P577
2005-04-01T00:00:00Z
P5875
P6179
1011922060